Zymeworks Common Company Insiders

Zymeworks Common Management Team Effectiveness

The company has return on total asset (ROA) of (0.1429) % which means that it has lost $0.1429 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2672) %, meaning that it created substantial loss on money invested by shareholders. Zymeworks Common's management efficiency ratios could be used to measure how well Zymeworks Common manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.01, whereas Return On Capital Employed is forecasted to decline to (0.32). At present, Zymeworks Common's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 271.1 M, whereas Non Currrent Assets Other are projected to grow to (12.6 B). The current year's Net Income Applicable To Common Shares is expected to grow to about 117.5 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 49.1 M. Zymeworks Common Stock retains a total of 74.84 Million outstanding shares. The majority of Zymeworks Common outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Zymeworks Common Stock to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Zymeworks Common Stock. Please pay attention to any change in the institutional holdings of Zymeworks Common Stock as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as Zymeworks Common in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Zymeworks Common, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Zymeworks Common Workforce Comparison

The company has Profit Margin (PM) of (0.77) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (17.56) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $17.56.

Zymeworks Common Insider Trading History

Zymeworks Common Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as Zymeworks Common Stock often depends on how effective the management is. Zymeworks Common management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zymeworks management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zymeworks management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of Zymeworks Common's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zymeworks Common's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zymeworks Common's management manipulating its earnings.

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.